Inflammation
Conditions
Brief summary
Coronary artery disease (CAD) is caused by myocardial ischemia, hypoxia or necrosis due to coronary artery stenosis, spasm or obstruction. Although standard drug therapy can greatly improve the prognosis of patients with CAD after percutaneous coronary interventions (PCI), these patients are still at high risk of major adverse cardiovascular and cerebrovascular events (MACCE). At present, the concept of residual inflammation risk (RIR) has aroused widespread concern. RIR is an important independent risk in patients with CAD. Previous studies indicated that hsCRP ≥ 2mg / L was the definition standard of RIR in CAD in European and American people. In China, the impact of dynamic changes of hsCRP and other inflammatory factors on MACCE in PCI population remains unclear. Therefore, in this study, the investigators plan to recruit patients undergoing PCI, and observe the impact of hsCRP and other inflammatory factors on the prognosis of these patients during long term follow-up at 17 hospitals in China.
Interventions
None listed
Sponsors
Shandong Provincial Hospital
The First Affiliated Hospital of Zhengzhou University
The First Affiliated Hospital of Xiamen University
Shanxi Cardiovascular Hospital
First People's Hospital of Xianyang
Yichang Central People's Hospital
Jingzhou Central Hospital
The First Hospital of Wuhan
Wuhan Central Hospital
Wuhan Fourth Hospital
Fifth Hospital in Wuhan
Chinese Academy of Medical Sciences, Fuwai Hospital
Wuhan Asia Heart Hospital
The First Affiliated Hospital of Anhui Medical University
Central Hospital of Enshi Tujia and Miao Autonomous Prefecture
Hubei University of Medicine
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Inclusion criteria
* Participants who understand and sign the informed consent voluntarily; * Age ≥ 18 years old and ≤ 80 years old, regardless of sex; * The hospitalized patients with coronary heart disease undergoing PCI; * Complete all planned PCI during hospitalization.
Exclusion criteria
* Acute, chronic or recurrent infectious diseases; * Immune diseases or immune-related diseases; * Long-term use of non-steroidal anti-inflammatory drugs, hormones, immunomodulatory and chemotherapy drugs; * Pregnant women, lactating women or women of childbearing age who do not use effective contraceptive measures; * The researchers determined that other conditions in which the patient was not suitable to participate in the clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| MACCE | 12 months | A composite of all-cause death, nonfatal myocardial infarction, nonfatal stroke, ischemia-driven revascularization |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| cardiovascular death | 12 months | Occurrence of cardiovascular death |
| nonfatal myocardial infarction | 12 months | Occurrence of nonfatal myocardial infarction |
| nonfatal stroke | 12 months | Occurrence of of nonfatal stroke |
| ischemia-driven revascularization | 12 months | Occurrence of ischemia-driven revascularization |
| all-cause death | 12 months | Occurrence of all-cause death |
| stent/scaffold thrombosis | 12 months | Occurrence of stent/scaffold thrombosis |
| in-stent restenosis | 12 months | Occurrence of in-stent restenosis |
| bleeding | 12 months | Occurrence of bleeding |
| hospitalization for unstable angina | 12 months | Occurrence of hospitalization for unstable angina |
Countries
China
Contacts
Primary ContactMiao Yu
Outcome results
None listed